IMS Health (NYSE:RX) has received approval from its stockholders to adopt the merger agreement for its acquisition by entities created by and affiliates of TPG Capital LP and the CPP Investment Board. More than 75% of the outstanding shares of IMS common stock as of December 28, 2009 voted to approve the proposal of the merger agreement. Approvals, consents, or consultations are required to consummate the merger. The consummation merger is subject to the satisfaction or waiver of other closing conditions. For more information, contact Gary Gatyas of IMS Health at 610.834.5338.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
IMS Health Incorporated (IMS) is a provider of market intelligence to the pharmaceutical and healthcare industries. IMS offers market intelligence products and services, including portfolio optimization capabilities; commercial effectiveness innovations; managed care and consumer health offerings, and consulting and services solutions. The Company’s information products are developed to meet the clients' needs by using data secured from a worldwide network of suppliers in more than 100 countries. During the year ended December 31, 2008, the Company acquired Robinson and James Research Pty Limited, Fourth Hurdle Consulting Limited, Health Benchmarks, Inc., RMBC Pharma Limited, and Skura Corporation, Inc.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
